Equities analysts expect OncoSec Medical Inc (NASDAQ:ONCS) to announce ($0.14) earnings per share for the current quarter, according to Zacks. Zero analysts have made estimates for OncoSec Medical’s earnings. OncoSec Medical reported earnings per share of ($0.18) in the same quarter last year, which indicates a positive year over year growth rate of 22.2%. The business is scheduled to announce its next quarterly earnings results on Wednesday, June 12th.
According to Zacks, analysts expect that OncoSec Medical will report full-year earnings of ($0.61) per share for the current financial year, with EPS estimates ranging from ($0.65) to ($0.56). For the next fiscal year, analysts expect that the company will report earnings of ($0.65) per share. Zacks’ EPS calculations are a mean average based on a survey of research firms that cover OncoSec Medical.
A number of equities analysts have weighed in on the stock. Zacks Investment Research downgraded shares of OncoSec Medical from a “buy” rating to a “hold” rating in a research note on Tuesday. Maxim Group reaffirmed a “buy” rating and issued a $5.00 target price on shares of OncoSec Medical in a research note on Monday, April 1st. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $3.13.
Shares of NASDAQ ONCS traded up $0.03 during trading on Friday, reaching $0.50. The company had a trading volume of 127,735 shares, compared to its average volume of 317,930. OncoSec Medical has a 52 week low of $0.42 and a 52 week high of $1.96.
Institutional investors and hedge funds have recently bought and sold shares of the stock. BlackRock Inc. grew its position in OncoSec Medical by 98.2% during the fourth quarter. BlackRock Inc. now owns 485,983 shares of the biotechnology company’s stock valued at $311,000 after acquiring an additional 240,843 shares during the last quarter. Bank of New York Mellon Corp grew its position in OncoSec Medical by 484.1% during the fourth quarter. Bank of New York Mellon Corp now owns 100,325 shares of the biotechnology company’s stock valued at $64,000 after buying an additional 83,150 shares during the period. Moloney Securities Asset Management LLC grew its position in OncoSec Medical by 117.4% during the fourth quarter. Moloney Securities Asset Management LLC now owns 50,000 shares of the biotechnology company’s stock valued at $32,000 after buying an additional 27,000 shares during the period. Northern Trust Corp grew its position in OncoSec Medical by 33.6% during the fourth quarter. Northern Trust Corp now owns 114,921 shares of the biotechnology company’s stock valued at $73,000 after buying an additional 28,914 shares during the period. Finally, Geode Capital Management LLC grew its position in OncoSec Medical by 72.5% during the fourth quarter. Geode Capital Management LLC now owns 388,688 shares of the biotechnology company’s stock valued at $248,000 after buying an additional 163,405 shares during the period. 6.39% of the stock is owned by institutional investors and hedge funds.
OncoSec Medical Company Profile
OncoSec Medical Incorporated, a biotechnology company, focuses on the development of cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer. Its lead product candidate is ImmunoPulse IL-12 that uses electroporation device to deliver a DNA-encoded interleukin-12 for reversing the immunosuppressive microenvironment in the treated tumor.
Recommended Story: Moving Average (MA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OncoSec Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoSec Medical and related companies with MarketBeat.com's FREE daily email newsletter.